155 related articles for article (PubMed ID: 17548594)
1. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity.
Da Silva DM; Fausch SC; Verbeek JS; Kast WM
J Immunol; 2007 Jun; 178(12):7587-97. PubMed ID: 17548594
[TBL] [Abstract][Full Text] [Related]
2. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
[TBL] [Abstract][Full Text] [Related]
3. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
[TBL] [Abstract][Full Text] [Related]
4. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Qian J; Dong Y; Pang YY; Ibrahim R; Berzofsky JA; Schiller JT; Khleif SN
Int J Cancer; 2006 Jun; 118(12):3022-9. PubMed ID: 16425257
[TBL] [Abstract][Full Text] [Related]
5. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells.
Fausch SC; Da Silva DM; Kast WM
Vaccine; 2005 Feb; 23(14):1720-9. PubMed ID: 15705478
[TBL] [Abstract][Full Text] [Related]
6. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88.
Yang R; Murillo FM; Delannoy MJ; Blosser RL; Yutzy WH; Uematsu S; Takeda K; Akira S; Viscidi RP; Roden RB
J Immunol; 2005 Jun; 174(12):7912-9. PubMed ID: 15944297
[TBL] [Abstract][Full Text] [Related]
7. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination.
Kaufmann AM; Nieland J; Schinz M; Nonn M; Gabelsberger J; Meissner H; Müller RT; Jochmus I; Gissmann L; Schneider A; Dürst M
Int J Cancer; 2001 Apr; 92(2):285-93. PubMed ID: 11291058
[TBL] [Abstract][Full Text] [Related]
8. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J
Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315
[TBL] [Abstract][Full Text] [Related]
9. A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells.
Wang X; Santin AD; Bellone S; Gupta S; Nakagawa M
Cancer Immunol Immunother; 2009 Feb; 58(2):301-8. PubMed ID: 18446336
[TBL] [Abstract][Full Text] [Related]
10. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells.
Yan M; Peng J; Jabbar IA; Liu X; Filgueira L; Frazer IH; Thomas R
Virology; 2004 Jul; 324(2):297-310. PubMed ID: 15207617
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro.
Warrino DE; Olson WC; Scarrow MI; D'Ambrosio-Brennan LJ; Guido RS; Da Silva DM; Kast WM; Storkus WJ
Hum Immunol; 2005 Jul; 66(7):762-72. PubMed ID: 16112023
[TBL] [Abstract][Full Text] [Related]
12. [Dendritic cells present particulate E7 protein of human papillomavirus and induce strong immunity].
Li J; Gao HQ; Zhao CL; Li LZ; Ji CY; Hou M; Plebaski M
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):932-6. PubMed ID: 15329282
[TBL] [Abstract][Full Text] [Related]
13. Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine.
García-Piñeres AJ; Hildesheim A; Trivett M; Williams M; Wu L; Kewalramani VN; Pinto LA
Eur J Immunol; 2006 Feb; 36(2):437-45. PubMed ID: 16385626
[TBL] [Abstract][Full Text] [Related]
14. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP.
Ruedl C; Storni T; Lechner F; Bächi T; Bachmann MF
Eur J Immunol; 2002 Mar; 32(3):818-25. PubMed ID: 11870626
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW
Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479
[TBL] [Abstract][Full Text] [Related]
17. Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells.
van Montfoort N; 't Hoen PA; Mangsbo SM; Camps MG; Boross P; Melief CJ; Ossendorp F; Verbeek JS
J Immunol; 2012 Jul; 189(1):92-101. PubMed ID: 22649202
[TBL] [Abstract][Full Text] [Related]
18. Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles.
Keller SA; Bauer M; Manolova V; Muntwiler S; Saudan P; Bachmann MF
J Immunol; 2010 Jan; 184(1):26-9. PubMed ID: 19949081
[TBL] [Abstract][Full Text] [Related]
19. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
20. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
